Advertisement

Topics

AMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz

01:17 EST 15 Feb 2018 | RTTNews

Today's Daily Dose brings you news about expanded FDA approval for AMAG's Makena and Abiomed's Impella; Bristol Myers' investment in Nektar; Galmed's disappointment over ARRIVE trial, and Vertex Pharma's encouraging results of NaV1.8 Inhibitor VX-150 in a mid-stage trial.

Original Article: AMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz

NEXT ARTICLE

More From BioPortfolio on "AMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...